Immuno-oncology 08/02/2018 Video: Striking the Balance Between Regulatory Opportunities and... A video interview with Peter Olaganju, Senior Technical Director at Bluebird Bio. With every new opportunity comes great challenges
Cell and Gene Therapy 01/02/2018 Video: Advanced Therapies 2025 Industry leaders discuss the past, present and future of advanced therapies in this inspiring video...
Cell and Gene Therapy 31/01/2018 Winning Friends and Influencing Logistics in the Cell and Gene... Dr Alina Depkat is the customer relations manager at time:matters, a subsidiary of Lufthansa, the largest airline in Europe. She is leading...
Cell and Gene Therapy 31/01/2018 European Drug Makers Take the First Footsteps into the US Gene... NOVARTIS HAS MADE HISTORY AS THE FIRST PHARMA COMPANY TO GAIN APPROVAL OF A CAR-T PRODUCT BY THE FDA AND CAN BE CROWNED DEFINITIVE WINNERS OF WHAT...
Cell and Gene Therapy 31/01/2018 EMA Hooks Bluebird and Kite with Enticing Regulatory Pathways KITE PHARMA’S RECENT ANNOUNCEMENT OF A MARKETING AUTHORISATION APPLICATION TO THE EMA FOR THEIR LEAD PRODUCT, AXICABTAGENE CILOLEUCEL, HAS RE...
Investment for Advanced Therapies 31/01/2018 Interview: Navigating the IP Landscape and Improving your Chances... Greg Bonfiglio is the founder and managing partner of Proteus, LLC, an investment and advisory firm that provides fund management and...
Investment for Advanced Therapies 31/01/2018 Report: Investment for Advanced Therapies This report provides a comprehensive guide to successfully investing in advanced therapies. It also outlines across six chapters each of the...
Cell and Gene Therapy 23/01/2018 Top 15 Cell and Gene Therapy Biotechs to Watch in 2018 We're keeping tabs on all the innovators and disruptors for you in the field of cell and gene therapies
Immuno-oncology 22/01/2018 15 Immuno-oncology Biotechs to Watch in 2018 We’re keeping tabs on the innovators and disruptors for you
Cell and Gene Therapy 22/01/2018 Regenerative Medicine Contract Manufacturing Organisations in Japan A summary of all of the regenerative medicine CMOs in Japan is presented in this infographic
Cell and Gene Therapy 22/01/2018 Cell and Gene Therapy Manufacturing Capacities in Europe 2017 Without capacity; manufacturing expertise; innovation and partnerships, advanced therapies cannot be commercialised nor delivered to patients ...
Cell and Gene Therapy 22/01/2018 Understanding the layers of complexity and working towards full... One of the main barriers to commercial viability for ATMPs is the supply chain, which contributes significantly to the overall cost of goods ...
Cell and Gene Therapy 18/01/2018 GMP Cell and Gene Therapy Manufacturing in the UK: Facilities,... The cell and gene therapy catapult review of MHRA licensed GMP manufacturing facilities in the UK provides an insightful picture of the capability...
Cell and Gene Therapy 11/01/2018 CRO Selection for Advanced Therapies How do you find the perfect CRO?
Cell and Gene Therapy 16/11/2017 An Investor’s Outlook on the Advanced Therapies Industry with... William Podd gives his perspective on investing in advanced therapies and advice for investors and biotechs alike
